Compare The Coca-Cola Co K (KO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Zoetis Inc — how do they compare? The Coca-Cola Co K trades at $86.85 (market cap $372.08B), while Zoetis Inc trades at $73.56 (market cap $31.14B). The key difference: The Coca-Cola Co K is far larger — about 11.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| KO | ZTS | |
|---|---|---|
Market Cap | $372.08B | $31.14B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $156.76 |
52-Week Low | $65.67 | $71.91 |
Enterprise Value | $399.26B | $38.70B |
Dividend Yield | 2.45% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.27, up 0.46% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with a 28.56% net margin and 44.23% ROE, supported by stable revenue growth to $47.94B in 2025. Recent news highlights institutional accumulation and dividend reliability, with the stock near key resistance at $87.
Outlook remains positive with a $95.83 consensus price target and 60% analyst buy ratings, though high valuation multiples (P/E 25.97) and debt levels pose risks. The stock offers steady income with a $0.53 quarterly dividend and growth potential from global demand trends, but faces headwinds from regional volatility and competitive pressures.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
